Stenotrophomonas maltophilia is an opportunistic multidrug-resistant pathogen increasingly associated with severe infections. Although cefiderocol has demonstrated potent in-vitro activity against S. maltophilia, clinical evidence remains limited. We performed a retrospective multicenter study including adult patients with S. maltophilia infections treated with cefiderocol in three tertiary-care hospitals between 2021-2024. Primary outcomes were 30-day mortality, clinical cure, microbiological eradication, and treatment-related adverse events. A review of the available literature was conducted. Fourteen patients were included (median age 61 years; median Charlson Comorbidity Index 5). Pneumonia was the most common infection (50%), while polymicrobial infections occurred in 42.9% of cases. TMP-SMX resistance was observed in 35.7% of isolates. Clinical cure and microbiological eradication were achieved in 64.3% and 75% of patients, respectively, whereas 30-day mortality was 21.4%. No cefiderocol-related adverse events were reported. These findings support cefiderocol as an effective and well-tolerated option for S. maltophilia infections, particularly when conventional therapies are limited.
Cefiderocol for Stenotrophomonas maltophilia infections. Real-world evidence from a multicenter study and a comprehensive literature review / Comi, M., Mancarella, G., Di Bari, S., Fiorentino, G., Del Borgo, C., Lichtner, M., Mastroianni, C.M., Oliva, A.. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1973-9478. - (2026), pp. 1-12. [10.1080/1120009X.2026.2685373]
Cefiderocol for Stenotrophomonas maltophilia infections. Real-world evidence from a multicenter study and a comprehensive literature review
Michela ComiPrimo
;Giulia Mancarella;Silvia Di Bari;Gianluca Fiorentino;Cosmo Del Borgo;Miriam Lichtner;Claudio Maria Mastroianni;Alessandra Oliva
2026
Abstract
Stenotrophomonas maltophilia is an opportunistic multidrug-resistant pathogen increasingly associated with severe infections. Although cefiderocol has demonstrated potent in-vitro activity against S. maltophilia, clinical evidence remains limited. We performed a retrospective multicenter study including adult patients with S. maltophilia infections treated with cefiderocol in three tertiary-care hospitals between 2021-2024. Primary outcomes were 30-day mortality, clinical cure, microbiological eradication, and treatment-related adverse events. A review of the available literature was conducted. Fourteen patients were included (median age 61 years; median Charlson Comorbidity Index 5). Pneumonia was the most common infection (50%), while polymicrobial infections occurred in 42.9% of cases. TMP-SMX resistance was observed in 35.7% of isolates. Clinical cure and microbiological eradication were achieved in 64.3% and 75% of patients, respectively, whereas 30-day mortality was 21.4%. No cefiderocol-related adverse events were reported. These findings support cefiderocol as an effective and well-tolerated option for S. maltophilia infections, particularly when conventional therapies are limited.| File | Dimensione | Formato | |
|---|---|---|---|
|
Comi_Cefiderocol_2026.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.32 MB
Formato
Adobe PDF
|
1.32 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


